Patents by Inventor Revati Shreeniwas

Revati Shreeniwas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PDE5 inhibitor powder formulations and methods relating thereto
    Patent number: 11911390
    Abstract: Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: February 27, 2024
    Assignee: Respira Therapeutics, Inc.
    Inventors: Zhen Xu, Hugh Smyth, Aileen Gibbons, Revati Shreeniwas, Pravin Soni, Dan Deaton, James Hannon, Stephen Lermer, Robert Curtis, Martin J. Donovan
  • PDE5 inhibitor powder formulations and methods relating thereto
    Patent number: 11806314
    Abstract: Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.
    Type: Grant
    Filed: January 20, 2022
    Date of Patent: November 7, 2023
    Assignee: Respira Therapeutics, Inc.
    Inventors: Zhen Xu, Hugh Smyth, Aileen Gibbons, Revati Shreeniwas, Pravin Soni, Dan Deaton, James Hannon, Stephen Lermer, Robert Curtis, Martin J. Donovan
  • Methods and compositions for treatment of pulmonary hypertension and other lung disorders
    Patent number: 11491161
    Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: November 8, 2022
    Assignee: Respira Therapeutics, Inc.
    Inventors: Jeffry Weers, Alain Romero, Hugh Smyth, Robert Curtis, Adaani Frost, Zhen Xu, Revati Shreeniwas, Martin Donovan
  • Methods and compositions for treatment of pulmonary hypertension and other lung disorders
    Patent number: 11491160
    Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.
    Type: Grant
    Filed: January 11, 2021
    Date of Patent: November 8, 2022
    Assignee: Respira Therapeutics, Inc.
    Inventors: Jeffry Weers, Alain Romero, Hugh Smyth, Robert Curtis, Adaani Frost, Zhen Xu, Revati Shreeniwas, Martin Donovan
  • METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS
    Publication number: 20220347183
    Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.
    Type: Application
    Filed: June 29, 2022
    Publication date: November 3, 2022
    Applicant: Respira Therapeutics, Inc.
    Inventors: Jeffry Weers, Alain Romero, Hugh Smyth, Robert Curtis, Adaani Frost, Zhen Xu, Revati Shreeniwas, Martin Donovan
  • PDE5 INHIBITOR POWDER FORMULATIONS AND METHODS RELATING THERETO
    Publication number: 20220143034
    Abstract: Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.
    Type: Application
    Filed: January 20, 2022
    Publication date: May 12, 2022
    Applicant: Respira Therapeutics, Inc.
    Inventors: Zhen Xu, Hugh Smyth, Aileen Gibbons, Revati Shreeniwas, Pravin Soni, Dan Deaton, James Hannon, Stephen Lermer, Robert Curtis, Martin J. Donovan
  • METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS
    Publication number: 20220079949
    Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.
    Type: Application
    Filed: November 23, 2021
    Publication date: March 17, 2022
    Applicant: Respira Therapeutics, Inc.
    Inventors: Jeffry Weers, Alain Romero, Hugh Smyth, Robert Curtis, Adaani Frost, Zhen Xu, Revati Shreeniwas, Martin Donovan
  • PDE5 INHIBITOR POWDER FORMULATIONS AND METHODS RELATING THERETO
    Publication number: 20220016126
    Abstract: Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.
    Type: Application
    Filed: March 24, 2021
    Publication date: January 20, 2022
    Inventors: Zhen Xu, Hugh Smyth, Aileen Gibbons, Revati Shreeniwas, Pravin Soni, Dan Deaton, James Hannon, Stephen Lermer, Robert Curtis, Martin J. Donovan
  • METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS
    Publication number: 20210205318
    Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.
    Type: Application
    Filed: January 11, 2021
    Publication date: July 8, 2021
    Inventors: Jeffry WEERS, Alain ROMERO, Hugh SMYTH, Robert CURTIS, Adaani FROST, Zhen XU, Revati SHREENIWAS, Martin DONOVAN
  • Methods for treatment of pulmonary hypertension
    Patent number: 10912778
    Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: February 9, 2021
    Assignee: RESPIRA THERAPEUTICS, INC.
    Inventors: Jeffry Weers, Alain Romero, Hugh Smyth, Robert Curtis, Adaani Frost, Zhen Xu, Revati Shreeniwas, Martin Donovan
  • METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS
    Publication number: 20200093830
    Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.
    Type: Application
    Filed: December 14, 2017
    Publication date: March 26, 2020
    Inventors: Jeffry WEERS, Alain ROMERO, Hugh SMYTH, Robert CURTIS, Adaani FROST, Zhen XU, Revati SHREENIWAS, Martin DONOVAN
  • PDE5 INHIBITOR POWDER FORMULATIONS AND METHODS RELATING THERETO
    Publication number: 20160317542
    Abstract: Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.
    Type: Application
    Filed: December 9, 2014
    Publication date: November 3, 2016
    Applicant: Respira Therapeutics, Inc.
    Inventors: Zhen Xu, Hugh Smyth, Aileen Gibbons, Revati Shreeniwas, Pravin Soni, Dan Deaton, James Hannon, Stephen Lermer, Robert Curtis
  • Methods of Use for Monomethyl Fumarate and Prodrugs Thereof
    Publication number: 20140057918
    Abstract: Methods of therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed.
    Type: Application
    Filed: August 22, 2013
    Publication date: February 27, 2014
    Applicant: XenoPort, Inc.
    Inventors: David J. Wustrow, Peter A. Virsik, Mark A. Gallop, Kenneth C. Cundy, Dmitri V. Lissin, Revati Shreeniwas